Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
If you undergo a Hematopoietic stem cell transplantation better known as a stem cell transplant for your multiple myeloma there is a good chance that you will develop cardiovascular disease. Heart-related side effects might be high blood pressure, diabetes or left ventrical heart damage.
Please give serious consideration to this life-threatening aspect of a stem cell transplant. This side effect may be immediate or occur years after the fact (aka “late stage”).
I was diagnosed with multiple myeloma (MM) in early 1994. I underwent an autologus stem cell transplant in ’95 and atrial fibrillation became permanent 15 years later.
This is referred to as a “late stage” side effect. If you underwent either cytoxan/cyclophosphomide or doxorubicin chemotherapy one after another your chances of heart damage will increase.
The question then is if you can do anything about your heart damage? My “heart healthy” therapies come from the literature (see the link below re CoQ10) and personal experience.
If you are reading this post BEFORE you undergo a stem cell transplant, you should begin CoQ10 supplementation immediately. The sooner you begin to supplement with COQ10, the better for your heart. Further, I recommend a heart healthy lifestyle including exercise, diet and stress management.
Ed Note- I wrote the above post in 2013. My CVD has slowly grown more pronounced and I have an appointment with a cardiologist in five days. I’ll keep you posted…
I’ve been living with chemotherapy-induced cardiomyopathy since my diagnosis in 12/2010. I have managed my cardiomyopathy, chronic atrial fibrillation, hypertension, etc. with evidence-based, non-conventional therapies every since. That’s correct- no conventional medications…none.
I am both a MM survivor and MM cancer coach. To learn more about managing possible heart damage scroll down the page, post a question or comment and I will reply ASAP.
Knowledge is Power, especially with multiple myeloma.
“Hematopoietic stem cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived from bone marrow, peripheral blood, or umbilical cord blood. It is a medical procedure in the fields of hematology and oncology, most often performed for patients with certain cancers of the blood or bone marrow, such as multiple myeloma or leukemia. In these cases, the recipient’s immune system is usually destroyed with radiation or chemotherapy before the transplantation. Infection and graft-versus-host disease is a major complication of allogenic HSCT.”
“HCT recipients may be at an increased risk of developing hypertension, diabetes and dyslipidemia (referred to as cardiovascular risk factors ([CVRFs]); and these can potentially increase the risk of cardiovascular disease (CVD)...
There was an incremental increase in 10-year incidence of CVD by number of CVRFs (4.7% [none], 7.0% [1 CVRF], 11.2% [≥2 CVRFs], p<0.01); the risk was especially high (15.0%) in patients with multiple CVRFs and pre-HCT exposure to anthracyclines or chest radiation…”
Mol Aspects Med. 1994;15 Suppl:s207-12.
“Two groups of children with acute lymphoblastic leukemia or non-Hodgkin lymphoma, treated with anthracyclines (ANT), were studied: group I, consisting of 10 patients, with coenzyme Q10 (CoQ) therapy; group II, consisting of 10 patients without CoQ therapy.
The ANT cumulative dose was 240 +/- 20.0 mg/m2 in group I and 252.0 +/- 20.1 mg/m2 in group II. Echocardiographic study was performed at the beginning, at the cumulative dose of 180 mg/m2 and at the end of therapy with ANT.
Percentage left ventricular fractional shortening (%LVFS) decreased from baseline (40.36 +/- 4.6) to end value (35.82 +/- 5.02) (P < 0.05) in group I; %LVFS decreased from baseline (39.89 +/- 4.37) to end value (33.43 +/- 3.46) (P < 0.002) in group II. Interventricular septum wall thickening decreased only in group II from baseline (46.10 +/- 10.1) to end therapy (27.00 +/- 18.54) (P < 0.01).
Septum wall motion abnormalities were detected only in 2 patients of group II.
These data demonstrate a protective effect of CoQ on cardiac function during therapy with ANT.”